A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

NCT ID: NCT07219966

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2028-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3537031 Period 1

Escalating doses administered subcutaneously (SC)

Group Type EXPERIMENTAL

LY3537031

Intervention Type DRUG

Administered SC

Placebo

Intervention Type DRUG

Administered SC

LY3537031 Period 2

Administered SC

Group Type EXPERIMENTAL

LY3537031

Intervention Type DRUG

Administered SC

Placebo

Intervention Type DRUG

Administered SC

Placebo

Administered SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3537031

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brenipatide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are seeking treatment and are motivated to stop or cut down on drinking.
* Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as

* self-inject study intervention
* store and use the provided blinded study intervention, as directed
* maintain electronic and paper study diaries, as applicable, and
* complete the required questionnaires.

Exclusion Criteria

* Have evidence of current or within the past 180 days prior to screening (V1), history of any substance use disorder(s) of any severity with a pattern of persistent illicit or nonprescribed substance use as indicated by clinical interview, except alcohol, nicotine, or caffeine.
* Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) and the ideation occurred within the past 6 months, or have answered "yes" to any of the suicide-related behaviors on the "Suicidal Behavior" portion of the C-SSRS and the behavior occurred within the past 6 months
* Have a history of advanced liver disease (including advanced liver fibrosis or cirrhosis), or alcohol-associated hepatitis based on either prior liver histology or imaging studies, such as transient elastography, ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), or Enhanced Liver Fibrosis score.
* Have participated in a clinical study and have received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before screening (V1).
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Parkway Medical Center

Birmingham, Alabama, United States

Site Status

Headlands Research - Scottsdale

Scottsdale, Arizona, United States

Site Status

UCLA Clinical & Translational Research Center (CTRC)

Los Angeles, California, United States

Site Status

Artemis Institute for Clinical Research

San Diego, California, United States

Site Status

UCSF Weill Institute for Neurosciences - Substance Use Disorders Clinic - Mission Bay

San Francisco, California, United States

Site Status

Mountain Mind - Denver

Denver, Colorado, United States

Site Status

K2 Medical Research - Maitland

Maitland, Florida, United States

Site Status

K2 Medical Research ORLANDO

Maitland, Florida, United States

Site Status

Life Arc Research Centers - Miami

Miami, Florida, United States

Site Status

Wellness Research Center

Miami, Florida, United States

Site Status

Charter Research - Orlando

Orlando, Florida, United States

Site Status

K2 Medical Research - Tampa

Tampa, Florida, United States

Site Status

Re:Cognition Health - Chicago

Chicago, Illinois, United States

Site Status

Maryland Treatment Centers - Mountain Manor Treatment Center

Baltimore, Maryland, United States

Site Status

Adams Clinical Bronx

The Bronx, New York, United States

Site Status

North Star Medical Research

Middleburg Heights, Ohio, United States

Site Status

Penn Medicine: University of Pennsylvania Health System

Philadelphia, Pennsylvania, United States

Site Status

Avera Research Institute - Sioux Falls

Sioux Falls, South Dakota, United States

Site Status

UT Southwestern Medical Center

Dallas, Texas, United States

Site Status

Adams Clinical Dallas

DeSoto, Texas, United States

Site Status

Pillar Clinical Research - Richardson

Richardson, Texas, United States

Site Status

Alpine Research Organization

Clinton, Utah, United States

Site Status

Re:Cognition Health

Fairfax, Virginia, United States

Site Status

University of Washington Medical Center - Montlake

Seattle, Washington, United States

Site Status

CIPREC

Buenos Aires, , Argentina

Site Status

Centro de Investigaciones Metabólicas (CINME)

Buenos Aires, , Argentina

Site Status

Mautalen Salud e Investigación

Buenos Aires, , Argentina

Site Status

Fundación Respirar

Buenos Aires, , Argentina

Site Status

Sanatorio Morra S.A.

Córdoba, , Argentina

Site Status

Instituto Kremer

Córdoba, , Argentina

Site Status

Centro Médico Luquez

Córdoba, , Argentina

Site Status

Global Psy Asociación Civil

La Plata, , Argentina

Site Status

Instituto de Investigaciones Clínicas Mar del Plata

Mar del Plata, , Argentina

Site Status

Resolution Psychopharmacology Research Institute

Mendoza, , Argentina

Site Status

Fundacion Estudios Clinicos

Rosario, , Argentina

Site Status

Fundación Innovaciencia

Rosario, , Argentina

Site Status

INECO Neurociencias Oroño

Rosario, , Argentina

Site Status

Instituto de Investigaciones Clinicas Rosario

Rosario, , Argentina

Site Status

Centro de Diagnóstico y Rehabilitación (CEDIR)

Santa Fe, , Argentina

Site Status

Clínica de Nefrología, Urología y Enfermedades Cardiovasculares

Santa Fe, , Argentina

Site Status

Clinica El Jardin

Santiago del Estero, , Argentina

Site Status

ANIMA Research

Alken, , Belgium

Site Status

Kormont

Kluisbergen, , Belgium

Site Status

Gezondheidshuis De Gloed

Machelen, , Belgium

Site Status

Meclinas

Mechelen, , Belgium

Site Status

Medisch Centrum Saffrou

Oudenaarde, , Belgium

Site Status

Beijing Anding Hospital - Affiliated Capital University of Medical Science

Beijing, , China

Site Status

Beijing HuiLongGuan Hospital

Beijing, , China

Site Status

The Second People's Hospital of Hunan Province

Changsha, , China

Site Status

The Second Xiangya Hospital of Central South University

Changsha, , China

Site Status

West China Hospital, Sichuan University

Cheng Du Shi, , China

Site Status

The Fourth People's Hospital of Chengdu

Chengdu, , China

Site Status

Guangzhou Brain Hospital

Guangzhou, , China

Site Status

The Seventh People's Hospital of Hangzhou

Hangzhou, , China

Site Status

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

Hangzhou, , China

Site Status

The Fourth Hospital of Harbin Medical University

Harbin, , China

Site Status

Huzhou Third Municipal Hospital

Huzhou, , China

Site Status

Shangdong Mental Health Center

Jinan, , China

Site Status

First Affiliated Hospital of Kunming Medical University

Kunming, , China

Site Status

The Third Hospital of Mianyang

Mianyang, , China

Site Status

The First Affiliated Hospital of Nanchang University

Nanchang, , China

Site Status

The Affilicated Kangning Hospital of Ningbo University

Ningbo, , China

Site Status

Shanghai Mental Health Center

Shanghai, , China

Site Status

Shenzhen Kangning Hospital

Shenzhen, , China

Site Status

The First Hospital of Hebei Medical University

Shijiazhuang, , China

Site Status

The Affiliated hospital of Southwest Medical University

Sichuan, , China

Site Status

Tianjin Anding Hospital

Tianjin, , China

Site Status

Wuhu Hospital of Beijing Anding hospital

Wuhu, , China

Site Status

Xi An Mental Health Center

Xi'an, , China

Site Status

Xiamen Xianyue Hospital

Xiamen, , China

Site Status

Xianyang Hospital of Yan'an University

Xianyang, , China

Site Status

Psychiatric Hospital of Henan Province

Xinxiang, , China

Site Status

Zhenjiang Mental Health Center

Zhenjiang, , China

Site Status

FutureMeds GmbH

Berlin, , Germany

Site Status

Velocity Clinical Research, Berlin

Berlin, , Germany

Site Status

Klinische Forschung Dresden

Dresden, , Germany

Site Status

Klinische Forschung Hamburg

Hamburg, , Germany

Site Status

Zentralinstitut für Seelische Gesundheit

Mannheim, , Germany

Site Status

Dedicated Research Site FutureMeds

Offenbach, , Germany

Site Status

Klinische forschung Schwerin GmbH

Schwerin, , Germany

Site Status

Takahashi Psychiatric Clinic

Ashiya, , Japan

Site Status

Tokyo-Eki Center-building Clinic

Chūōku, , Japan

Site Status

Ai Sakura Clinic

Fukuoka, , Japan

Site Status

Hiro Mental Clinic

Fukuoka, , Japan

Site Status

Kuramitsu Hospital

Fukuoka, , Japan

Site Status

Rainbow and Sea Hospital

Karatsu, , Japan

Site Status

Kariya Hospital

Kariya, , Japan

Site Status

Tatsuta Clinic

Kobe, , Japan

Site Status

Arata Clinic

Nagasaki, , Japan

Site Status

Yokogawa Ekimae Clinic

Nishi, , Japan

Site Status

Teine Keijinkai Hospital

Sapporo, , Japan

Site Status

Sangenjaya Shinkeika Shinryonaika Clinic

Setagaya City, , Japan

Site Status

Hillside Clinic Jingumae

Shibuya City, , Japan

Site Status

Keiai Clinic

Shinjuku-ku, , Japan

Site Status

Sakurazaka Clinic SophyAnce

Tokyo, , Japan

Site Status

Noguchi Naika Clinic

Tokyo, , Japan

Site Status

Tsukuba University Hospital

Tsukuba, , Japan

Site Status

Maekawa Medical Clinic

Yokohama, , Japan

Site Status

Makoto Kokoro No Clinic

Yokohama, , Japan

Site Status

National Hospital Organization Hizen Psychiatric Medical Center

Yoshinogari-cho, Kanzaki-gun, , Japan

Site Status

Pusan National University Yangsan Hospital

Busan, , South Korea

Site Status

Chungbuk National University Hospital

Cheongju-si, , South Korea

Site Status

Hanyang University Guri Hospital

Guri-si, , South Korea

Site Status

Inha University Hospital

Incheon, , South Korea

Site Status

Kyungpook National University Hospital

Junggu, , South Korea

Site Status

Gachon University Gil Medical Center

Namdong-gu, , South Korea

Site Status

Konyang University Hospital

Seogu, , South Korea

Site Status

Konyang University Hospital

Seogu, , South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Hanyang University Seoul Hospital

Seoul, , South Korea

Site Status

The Catholic Univ. of Korea Seoul St. Mary's Hospital

Seoul, , South Korea

Site Status

The Catholic University of Korea, Uijeongbu St. Mary's Hospital

Uijeongbu-si, , South Korea

Site Status

Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Hualien City, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Mackay Memorial Hospital

Taipei, , Taiwan

Site Status

Taipei City Hospital - Songde Branch

Taipei, , Taiwan

Site Status

Tri-Service General Hospital

Taipei, , Taiwan

Site Status

Chang Gung Medical Foundation-Linkou Branch

Taoyuan District, , Taiwan

Site Status

Charlton Lane

Cheltenham, , United Kingdom

Site Status

Edinburgh Royal Infirmary

Edinburgh, , United Kingdom

Site Status

Queen Elizabeth University Hospital

Glasgow, , United Kingdom

Site Status

National Institute for Health Research (NIHR) - King's Clinical Research Facility (CRF)

London, , United Kingdom

Site Status

Clerkenwell Health - London - Baker Street

London, , United Kingdom

Site Status

Salford Royal Hospital

Salford, , United Kingdom

Site Status

Southampton General Hospital

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Belgium China Germany Japan South Korea Taiwan United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Role: CONTACT

Phone: 1-317-615-4559

Email: [email protected]

Physicians interested in becoming principal investigators please contact

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

https://trials.lilly.com/en-US/trial/662497

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-522313-38-00

Identifier Type: CTIS

Identifier Source: secondary_id

JS2-MC-GZME

Identifier Type: OTHER

Identifier Source: secondary_id

27346

Identifier Type: -

Identifier Source: org_study_id